Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 1/20 | 0.66 |
| ▸ | PTPRO | Q16827 | 1/20 | 0.66 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | STAT3 | P40763 | 13/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | MPL | P40238 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1734788 | 0.87 | PTPN11 (0.85) | PTPN11PTPROBCL2L1MCL1KDM4E | |
| SCHEMBL1815705 | 0.86 | PTPN11 (0.48) | PTPN11PTPROKDM4EALDH1A1POLB | |
| SCHEMBL1733846 | 0.85 | PTPN11 (0.51) | PTPN11PTPROSTAT3 | |
| SCHEMBL1736063 | 0.80 | PTPN11 (0.53) | PTPN11PTPROSTAT3CNR2 | |
| SCHEMBL1733819 | 0.80 | STAT3 (0.49) | PTPN11PTPROSTAT3 | |
| SCHEMBL1733827 | 0.80 | PTPN11 (1.00) | PTPN11PTPROBCL2L1MCL1KDM4E | |
| SCHEMBL1734802 | 0.80 | PTPN11 (0.89) | PTPN11PTPROBCL2L1MCL1KDM4E | |
| SCHEMBL1733825 | 0.79 | PTPN11 (0.58) | PTPN11PTPROSTAT3CNR2 | |
| Hydrochloric Acid SCHEMBL1815540 | 0.79 | PTPN11 (0.98) | PTPN11PTPROBCL2L1MCL1KDM4E | |
| SCHEMBL2848964 | 0.78 | PTPN11 (0.60) | PTPN11PTPROMCL1STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947851-B2 | 1,1′-(1,2-ethynediyl)bis-benzene derivatives as PTP 1-B inhibitors | MERCK SERONO SA (CH) | 2011-05-24 | — | — | US | disclosed |
| US-20090029903-A1 | 1,1'-(1,2-Ethynediyl)Bis-Benzene Derivatives As Ptp 1-B Inhibitors | MERCK SERONO SA (CH) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029903-A1 | 1,1'-(1,2-Ethynediyl)Bis-Benzene Derivatives As Ptp 1-B Inhibitors | PTPRS, PTPRZ1, PTP4A1 | PTPN11 38/4885PTPRO 4/4885BCL2L1 665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.